Journal of Pharmaceutical Care & Health Systems
Open Access
ISSN: 2376-0419
+44 1300 500008
ISSN: 2376-0419
+44 1300 500008
Abdelmoneim Awad and Fatemah Alsaleh
Kuwait University, Kuwait
Scientific Tracks Abstracts: J Pharma Care Health Sys
Identification of individuals with metabolic syndrome (MetS) and those who are at risk of developing coronary heart disease (CHD) and type-2 diabetes (T2D) is vital to delay or even prevent the development of T2D and modify the CHD risk levels. The present study was designed to determine the prevalence of MetS, and to estimate the 10-year risk for developing T2D and CHD among the general population in Kuwait. A descriptive, cross-sectional survey was undertaken in 1800 individuals without diabetes or a history of cardiovascular disease. The questionnaire was developed using the Finnish Diabetes Risk Score, Framingham Risk Score and the 2009 Joint Statement criteria for diagnosis of MetS as a framework. The response rate was 89.4%. Sixty one percent of responders were either overweight or obese. Twelve percent had BP ΓΆΒ?Β¥140/90 mm Hg. Twenty eight percent had fasting plasma glucose levels ΓΆΒ?Β¥ 5.6 mmol/l, of whom 86.0 % and 14.0% had impaired fasting glucose and screen detected T2D, respectively. MetS was present in 31.8%. Almost 30% were at moderate, high, or very high risk of developing T2D, while 17.6% were at moderate/high risk of developing CHD. Almost 9% were at moderate/high/very high risk of developing both T2D/CHD. T2D risk was higher for females compared to males (p<0.001); however, the pattern was reversed in terms of the risk of developing CHD or T2D/CHD. The risk of developing T2D, CHD, or T2D/CHD was greater among those aged ΓΆΒ?Β¥ 45 years, and those having MetS (p<0.001). The current findings highlight the need for multifaceted interventions for prevention.
Abdelmoneim Awad has completed his PhD from Robert Gordon University, Aberdeen. He is a Professor of Clinical Pharmacy and Chairman of the Department of Pharmacy Practice, Faculty of Pharmacy, Kuwait University. He has published 40 peer-review papers and presented 35 abstracts in international conferences and is serving as an Editorial Board Member of reputed journals. He is a Reviewer of 24 professional journals. He is a Member of the American College of Clinical Pharmacy, Gulf College of Clinical Pharmacy and the European Society of Clinical Pharmacy.
Email: amoneim@hsc.edu.kw